New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.
Reduction of anticancer prodrugs such as ctc-[PtCl(2)(CH(3)CO(2))(2)(NH(3))(Am)] can yield three products in addition to the expected cis-[PtCl(2)(NH(3))(Am)]. A possible explanation is that reduction proceeds by several pathways where in addition to the loss of two axial ligands, one axial (acetato) and one equatorial (chlorido) ligand, or two equatorial ligands are eliminated.
Nemirovski
Alina
A
Department of Medicinal Chemistry and Natural Products, Institute of Drug Research, The Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Vinograd
Inbal
I
Takrouri
Khuloud
K
Mijovilovich
Ana
A
Rompel
Annette
A
Gibson
Dan
D
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D009944:Organoplatinum Compounds / Q000737:chemistry*; D010084:Oxidation-Reduction; D011355:Prodrugs / Q000737:chemistry* / Q000494:pharmacology; D056928:X-Ray Absorption Spectroscopy
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011355:Prodrugs